Fusobacterium nucleatum in tumors: from tumorigenesis to tumor metastasis and tumor resistance

References

• Brennan CA, Garrett WS. Fusobacterium nucleatum - symbiont, opportunist and oncobacterium. Nat Rev Microbiol. 2019;17(3):156–19. doi:10.1038/s41579-018-0129-6.
   PubMed Web of Science ®Google Scholar
• Zhang L, Liu Y, Zheng HJ, Zhang CP. The Oral Microbiota May Have Influence on Oral Cancer, Front Cell Infect Microbiol. Front Cell Infect Microbiol. 2019. 9:476. doi:10.3389/fcimb.2019.00476.
   PubMed Web of Science ®Google Scholar
• Zhao H, Chu M, Huang Z, Yang X, Ran S, Hu B, Zhang C, Liang J. Variations in oral microbiota associated with oral cancer. Sci Rep. 2017;7(1):11773. doi:10.1038/s41598-017-11779-9.
   PubMed Web of Science ®Google Scholar
• Shao D, Vogtmann E, Liu A, Qin J, Chen W, Abnet CC, Wei W. Microbial characterization of esophageal squamous cell carcinoma and gastric cardia adenocarcinoma from a high-risk region of China. Cancer. 2019;125(22):3993–4002. doi:10.1002/cncr.32403.
   PubMed Web of Science ®Google Scholar
• Yamamura K, Baba Y, Nakagawa S, Mima K, Miyake K, Nakamura K, Sawayama H, Kinoshita K, Ishimoto T, Iwatsuki M, et al. Human Microbiome Fusobacterium Nucleatum in Esophageal Cancer Tissue Is Associated with Prognosis. Clin Cancer Res. 2016;22(22):5574–5581. doi:10.1158/1078-0432.Ccr-16-1786.
   PubMed Web of Science ®Google Scholar
• Lee SA, Liu F, Riordan SM, Lee CS, Zhang L. Global Investigations of Fusobacterium nucleatum in Human Colorectal Cancer. Front Oncol. 2019;9:566. doi:10.3389/fonc.2019.00566.
   PubMed Web of Science ®Google Scholar
• Castaño-Rodríguez N, Goh KL, Fock KM, Mitchell HM, Kaakoush NO. Dysbiosis of the microbiome in gastric carcinogenesis. Sci Rep. 2017;7(1):15957. doi:10.1038/s41598-017-16289-2.
   PubMedGoogle Scholar
• Hsieh YY, Tung SY, Pan HY, Yen CW, Xu HW, Lin YJ, Deng YF, Hsu WT, Wu CS, Li C. Increased abundance of Clostridium and Fusobacterium in gastric microbiota of patients with gastric cancer in Taiwan. Sci Rep. 2018;8(1):158. doi:10.1038/s41598-017-18596-0.
   PubMedGoogle Scholar
• Alkharaan H, Lu L, Gabarrini G, Halimi A, Ateeb Z, Sobkowiak MJ, Davanian H, Fernández Moro C, Jansson L, Del Chiaro M, et al., Circulating and salivary antibodies to Fusobacterium nucleatum are associated with cystic pancreatic neoplasm malignancy, Front Immunol 11 (2020) 2003. 10.3389/fimmu.2020.02003
   PubMed Web of Science ®Google Scholar
• Parhi L, Alon-Maimon T, Sol A, Nejman D, Shhadeh A, Fainsod-Levi T, Yajuk O, Isaacson B, Abed J, Maalouf N, et al. Breast cancer colonization by Fusobacterium nucleatum accelerates tumor growth and metastatic progression. Nat Commun. 2020;11(1):3259. doi:10.1038/s41467-020-16967-2.
   PubMed Web of Science ®Google Scholar
• Fan Z, Tang P, Li C, Yang Q, Xu Y, Su C, Li L. Fusobacterium nucleatum and its associated systemic diseases: epidemiologic studies and possible mechanisms. J Oral Microbiol. 2023;15(1):2145729. doi:10.1080/20002297.2022.2145729.
   PubMed Web of Science ®Google Scholar
• Hashemi Goradel N, Heidarzadeh S, Jahangiri S, Farhood B, Mortezaee K, Khanlarkhani N, Negahdari B. Fusobacterium nucleatum and colorectal cancer: a mechanistic overview. J Cell Physiol. 2019;234(3):2337–2344. doi:10.1002/jcp.27250.
   PubMed Web of Science ®Google Scholar
• Chen Z, Wong PY, Ng CWK, Lan L, Fung S, Li JW, Cai L, Lei P, Mou Q, Wong SH, et al. The intersection between oral microbiota, host gene methylation and patient outcomes in head and neck squamous cell carcinoma. Cancers Basel. 2020;12(11):3425. doi:10.3390/cancers12113425.
   PubMed Web of Science ®Google Scholar
• Zhao K, Hu Y. Microbiome harbored within tumors: a new chance to revisit our understanding of cancer pathogenesis and treatment. Signal Transduct Target Ther. 2020;5(1):136. doi:10.1038/s41392-020-00244-1.
   PubMed Web of Science ®Google Scholar
• Alon-Maimon T, Mandelboim O, Bachrach G. Fusobacterium nucleatum and cancer. Periodontol 2000. 2022;89(1):166–180. doi:10.1111/prd.12426.
   PubMed Web of Science ®Google Scholar
• Yamamura K, Izumi D, Kandimalla R, Sonohara F, Baba Y, Yoshida N, Kodera Y, Baba H, Goel A. Intratumoral Fusobacterium Nucleatum levels predict therapeutic response to neoadjuvant chemotherapy in esophageal squamous cell carcinoma. Clin Cancer Res. 2019;25(20):6170–6179. doi:10.1158/1078-0432.CCR-19-0318.
   PubMed Web of Science ®Google Scholar
• Ai L, Xu A, Xu J. Roles of PD-1/PD-L1 pathway: signaling, cancer, and beyond. Adv Exp Med Biol. 2020;1248:33–59. doi:10.1007/978-981-15-3266-5_3.
   PubMed Web of Science ®Google Scholar
• Abed J, Maalouf N, Manson AL, Earl AM, Parhi L, Emgård JEM, Klutstein M, Tayeb S, Almogy G, Atlan KA, et al. Colon cancer-associated Fusobacterium nucleatum may originate from the oral cavity and reach colon tumors via the circulatory system. Front Cell Infect Microbiol. 2020;10:400. doi:10.3389/fcimb.2020.00400.
   PubMedGoogle Scholar
• Meng Q, Gao Q, Mehrazarin S, Tangwanichgapong K, Wang Y, Huang Y, Pan Y, Robinson S, Liu Z, Zangiabadi A, et al. Fusobacterium nucleatum secretes amyloid-like FadA to enhance pathogenicity. EMBO Rep. 2021;22(7):e52891. doi:10.15252/embr.202152891.
   PubMed Web of Science ®Google Scholar
• Wirbel J, Pyl PT, Kartal E, Zych K, Kashani A, Milanese A, Fleck JS, Voigt AY, Palleja A, Ponnudurai R, et al. Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer. Nat Med. 2019;25(4):679–689. doi:10.1038/s41591-019-0406-6.
   PubMed Web of Science ®Google Scholar
• Abed J, Emgård JE, Zamir G, Faroja M, Almogy G, Grenov A, Sol A, Naor R, Pikarsky E, Atlan KA, et al. Fap2 Mediates Fusobacterium nucleatum Colorectal Adenocarcinoma Enrichment by Binding to Tumor-Expressed Gal-GalNAc. Cell Host & Microbe. 2016;20(2):215–225. doi:10.1016/j.chom.2016.07.006.
   PubMed Web of Science ®Google Scholar
• Wang N, Fang JY. Fusobacterium nucleatum, a key pathogenic factor and microbial biomarker for colorectal cancer. Trends Microbiol. 2023;31(2):159–172. doi:10.1016/j.tim.2022.08.010.
   PubMed Web of Science ®Google Scholar
• Abed J, Maalouf N, Parhi L, Chaushu S, Mandelboim O, Bachrach G. Tumor Targeting by Fusobacterium nucleatum: A Pilot Study and Future Perspectives. Front Cell Infect Microbiol. 2017;7:295. doi:10.3389/fcimb.2017.00295.
   PubMed Web of Science ®Google Scholar
• McIlvanna E, Linden GJ, Craig SG, Lundy FT, James JA, Fusobacterium nucleatum and oral cancer: a critical review, BMC Cancer 21 (1) (2021) 1212. 10.1186/s12885-021-08903-4
   PubMed Web of Science ®Google Scholar
• Amer A, Galvin S, Healy CM, Moran GP. The microbiome of potentially malignant oral leukoplakia exhibits enrichment for Fusobacterium, Leptotrichia, Campylobacter, and Rothia Species. Front Microbiol. 2017;8:2391. doi:10.3389/fmicb.2017.02391.
   PubMed Web of Science ®Google Scholar
• Chen T, Li Q, Wu J, Wu Y, Peng W, Li H, Wang J, Tang X, Peng Y, Fu X. Fusobacterium nucleatum promotes M2 polarization of macrophages in the microenvironment of colorectal tumours via a TLR4-dependent mechanism. Cancer Immunol Immunother. 2018;67(10):1635–1646. doi:10.1007/s00262-018-2233-x.
   PubMed Web of Science ®Google Scholar
• OuYang LY, Wu XJ, Ye SB, Zhang RX, Li ZL, Liao W, Pan ZZ, Zheng LM, Zhang XS, Wang Z, et al. Tumor-induced myeloid-derived suppressor cells promote tumor progression through oxidative metabolism in human colorectal cancer. J Transl Med. 2015;13(1):47. doi:10.1186/s12967-015-0410-7.
   PubMedGoogle Scholar
• Hu L, Liu Y, Kong X, Wu R, Peng Q, Zhang Y, Zhou L, Duan L. Fusobacterium nucleatum facilitates M2 macrophage polarization and colorectal carcinoma progression by activating TLR4/NF-κB/S100A9 cascade. Front Immunol. 2021;12:658681. doi:10.3389/fimmu.2021.658681.
   PubMed Web of Science ®Google Scholar
• Mima K, Sukawa Y, Nishihara R, Qian ZR, Yamauchi M, Inamura K, Kim SA, Masuda A, Nowak JA, Nosho K, et al. Fusobacterium nucleatum and T cells in colorectal carcinoma. JAMA Oncol. 2015;1(5):653–661. doi:10.1001/jamaoncol.2015.1377.
   PubMed Web of Science ®Google Scholar
• Gur C, Ibrahim Y, Isaacson B, Yamin R, Abed J, Gamliel M, Enk J, Bar-On Y, Stanietsky-Kaynan N, Coppenhagen-Glazer S, et al. Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack. Immunity. 2015;42(2):344–355. doi:10.1016/j.immuni.2015.01.010.
   PubMed Web of Science ®Google Scholar
• Engevik MA, Danhof HA, Ruan W, Engevik AC, Chang-Graham AL, Engevik KA, Shi Z, Zhao Y, Brand CK, Krystofiak ES, et al. Fusobacterium nucleatum Secretes Outer Membrane Vesicles and Promotes Intestinal Inflammation. mBio. 2021;12(2). doi:10.1128/mBio.02706-20.
   PubMed Web of Science ®Google Scholar
• Wu Y, Wu J, Chen T, Li Q, Peng W, Li H, Tang X, Fu X. Fusobacterium nucleatum Potentiates Intestinal Tumorigenesis in Mice via a Toll-Like Receptor 4/p21-Activated Kinase 1 Cascade. Dig Dis Sci. 2018;63(5):1210–1218. doi:10.1007/s10620-018-4999-2.
   PubMed Web of Science ®Google Scholar
• Yin H, Miao Z, Wang L, Su B, Liu C, Jin Y, Wu B, Han H, Yuan X. Fusobacterium nucleatum promotes liver metastasis in colorectal cancer by regulating the hepatic immune niche and altering gut microbiota, aging (Albany NY. 2022.14 (4). 1941–1958.10.18632/aging.203914
   Google Scholar
• Yang Y, Weng W, Peng J, Hong L, Yang L, Toiyama Y, Gao R, Liu M, Yin M, Pan C, et al. Fusobacterium nucleatum increases proliferation of colorectal cancer cells and tumor development in mice by activating toll-like receptor 4 signaling to nuclear factor-κB, and up-regulating expression of MicroRNA-21. Gastroenterology. 2017;152(4):851–866.e24. doi:10.1053/j.gastro.2016.11.018.
   PubMed Web of Science ®Google Scholar
• Hong J, Guo F, Lu SY, Shen C, Ma D, Zhang X, Xie Y, Yan T, Yu T, Sun T, et al. F.Nucleatum targets lncRNA ENO1-IT1 to promote glycolysis and oncogenesis in colorectal cancer. Gut. 2021;70(11):2123–2137. doi:10.1136/gutjnl-2020-322780.
   PubMed Web of Science ®Google Scholar
• Guo S, Chen J, Chen F, Zeng Q, Liu WL, Zhang G. Exosomes derived from Fusobacterium nucleatum-infected colorectal cancer cells facilitate tumour metastasis by selectively carrying miR-1246/92b-3p/27a-3p and CXCL16. Gut. 2020;70(8):1507–1519. doi:10.1136/gutjnl-2020-321187.
   Web of Science ®Google Scholar
• Zheng X, Liu R, Zhou C, Yu H, Luo W, Zhu J, Liu J, Zhang Z, Xie N, Peng X, et al. ANGPTL4-mediated promotion of glycolysis facilitates the colonization of Fusobacterium nucleatum in colorectal cancer. Cancer Res. 2021;81(24):6157–6170. doi:10.1158/0008-5472.Can-21-2273.
   PubMed Web of Science ®Google Scholar
• Chen S, Su T, Zhang Y, Lee A, He J, Ge Q, Wang L, Si J, Zhuo W, Wang L. Fusobacterium nucleatum promotes colorectal cancer metastasis by modulating KRT7-AS/KRT7. Gut Microbes. 2020;11(3):511–525. doi:10.1080/19490976.2019.1695494.
   PubMed Web of Science ®Google Scholar
• Mohan CD, Rangappa S, Nayak SC, Sethi G, Rangappa KS. Paradoxical functions of long noncoding RNAs in modulating STAT3 signaling pathway in hepatocellular carcinoma. Biochimica Et Biophysica Acta (BBA) - Reviews On Cancer. 2021;1876(1):188574. doi:10.1016/j.bbcan.2021.188574.
   PubMed Web of Science ®Google Scholar
• Lu X, Xu Q, Tong Y, Zhang Z, Dun G, Feng Y, Tang J, Han D, Mao Y, Deng L, et al. Long non-coding RNA EVADR induced by Fusobacterium nucleatum infection promotes colorectal cancer metastasis. Cell Rep. 2022;40(3):111127. doi:10.1016/j.celrep.2022.111127.
   PubMed Web of Science ®Google Scholar
• Kong C, Yan X, Zhu Y, Zhu H, Luo Y, Liu P, Ferrandon S, Kalady MF, Gao R, He J, et al. Fusobacterium Nucleatum Promotes the Development of Colorectal Cancer by Activating a Cytochrome P450/Epoxyoctadecenoic Acid Axis via TLR4/Keap1/NRF2 Signaling. Cancer Res. 2021;81(17):4485–4498. doi:10.1158/0008-5472.Can-21-0453.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang L, Zheng S, Li M, Xu C, Jia D, Qi Y, Hou T, Wang L, Wang B, et al. Fusobacterium nucleatum promotes colorectal cancer cells adhesion to endothelial cells and facilitates extravasation and metastasis by inducing ALPK1/NF-κB/ICAM1 axis. Gut Microbes. 2022;14(1):2038852. doi:10.1080/19490976.2022.2038852.
   PubMed Web of Science ®Google Scholar
• Chen Y, Chen Y, Zhang J, Cao P, Su W, Deng Y, Zhan N, Fu X, Huang Y, Dong W. Fusobacterium nucleatum promotes metastasis in colorectal cancer by activating autophagy signaling via the upregulation of CARD3 expression. Theranostics. 2020;10(1):323–339. doi:10.7150/thno.38870.
   PubMed Web of Science ®Google Scholar
• Chen S, Zhang L, Li M, Zhang Y, Sun M, Wang L, Lin J, Cui Y, Chen Q, Jin C, et al. Fusobacterium nucleatum reduces METTL3-mediated m(6)A modification and contributes to colorectal cancer metastasis. Nat Commun. 2022;13(1):1248. doi:10.1038/s41467-022-28913-5.
   PubMed Web of Science ®Google Scholar
• Li R, Hu Y, Hou S. An Exploration of Oral-Gut Pathogens Mediating Immune Escape of Pancreatic Cancer via miR-21/PTEN Axis. Front Microbiol. 2022;13:928846. doi:10.3389/fmicb.2022.928846.
   PubMed Web of Science ®Google Scholar
• Koi M, Okita Y, Carethers JM. Fusobacterium nucleatum Infection in Colorectal Cancer: Linking Inflammation, DNA Mismatch Repair and Genetic and Epigenetic Alterations. J Anus Rectum Colon. 2018;2(2):37–46. doi:10.23922/jarc.2017-055.
   PubMed Web of Science ®Google Scholar
• Sayed IM, Chakraborty A, Abd El-Hafeez AA, Sharma A, Sahan AZ, Huang WJM, Sahoo D, Ghosh P, Hazra TK, Das S. The DNA glycosylase NEIL2 suppresses fusobacterium-infection-induced inflammation and DNA damage in colonic epithelial cells. Cells. 2020;9(9):1980. doi:10.3390/cells9091980.
   PubMed Web of Science ®Google Scholar
• Ternes D, Tsenkova M, Pozdeev VI, Meyers M, Koncina E, Atatri S, Schmitz M, Karta J, Schmoetten M, Heinken A, et al. The gut microbial metabolite formate exacerbates colorectal cancer progression. Nat Metab. 2022;4(4):458–475. doi:10.1038/s42255-022-00558-0.
   PubMedGoogle Scholar
• Ternes D, Karta J, Tsenkova M, Wilmes P, Haan S, Letellier E. Microbiome in colorectal cancer: how to get from meta-omics to mechanism? Trends Microbiol. 2020;28(5):401–423. doi:10.1016/j.tim.2020.01.001.
   PubMed Web of Science ®Google Scholar
• Connors J, Dawe N, Van Limbergen J. The Role of Succinate in the Regulation of Intestinal Inflammation. Nutrients. 2018;11(1):25. doi:10.3390/nu11010025.
   PubMed Web of Science ®Google Scholar
• Brennan CA, Clay SL, Lavoie SL, Bae S, Lang JK, Fonseca-Pereira D, Rosinski KG, Ou N, Glickman JN, Garrett WS. Fusobacterium nucleatum drives a pro-inflammatory intestinal microenvironment through metabolite receptor-dependent modulation of IL-17 expression. Gut Microbes. 2021;13(1):1987780. doi:10.1080/19490976.2021.1987780.
   PubMed Web of Science ®Google Scholar
• Rubinstein MR, Wang X, Liu W, Hao Y, Cai G, Han YW. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. Cell Host & Microbe. 2013;14(2):195–206. doi:10.1016/j.chom.2013.07.012.
   PubMed Web of Science ®Google Scholar
• Kaplan CW, Ma X, Paranjpe A, Jewett A, Lux R, Kinder-Haake S, Shi W. Fusobacterium nucleatum outer membrane proteins Fap2 and RadD induce cell death in human lymphocytes. Infect Immun. 2010;78(11):4773–4778. doi:10.1128/iai.00567-10.
   PubMed Web of Science ®Google Scholar
• Binder Gallimidi A, Fischman S, Revach B, Bulvik R, Maliutina A, Rubinstein AM, Nussbaum G, Elkin M. Periodontal pathogens Porphyromonas gingivalis and Fusobacterium nucleatum promote tumor progression in an oral-specific chemical carcinogenesis model. Oncotarget. 2015;6(26):22613–22623. doi:10.18632/oncotarget.4209.
   PubMedGoogle Scholar
• Vyhnalova T, Danek Z, Gachova D, Linhartova PB. The role of the oral microbiota in the etiopathogenesis of oral squamous cell carcinoma. Microorganisms. 2021;9(8):1549. doi:10.3390/microorganisms9081549.
   PubMed Web of Science ®Google Scholar
• Metsäniitty M, Hasnat S, Salo T, Salem A. Oral microbiota—A new frontier in the pathogenesis and management of head and neck cancers. Cancers Basel. 2021;14(1):46. doi:10.3390/cancers14010046.
   PubMed Web of Science ®Google Scholar
• Geng F, Zhang Y, Lu Z, Zhang S, Pan Y. Fusobacterium nucleatum caused DNA damage and promoted cell proliferation by the Ku70/p53 pathway in oral cancer cells. DNA Cell Biol. 2020;39(1):144–151. doi:10.1089/dna.2019.5064.
   PubMed Web of Science ®Google Scholar
• Chen G, Gao C, Jiang S, Cai Q, Li R, Sun Q, Xiao C, Xu Y, Wu B, Zhou H. 2023. Fusobacterium nucleatum outer membrane vesicles activate autophagy to promote oral cancer metastasis. J Adv Res. doi:10.1016/j.jare.2023.04.002.
   Google Scholar
• Hsueh CY, Huang Q, Gong H, Shen Y, Sun J, Lau HC, Zhang D, Tang D, Wu C, Guo Y, et al. A positive feed-forward loop between Fusobacterium nucleatum and ethanol metabolism reprogramming drives laryngeal cancer progression and metastasis. iScience. 2022;25(2):103829. doi:10.1016/j.isci.2022.103829.
   PubMed Web of Science ®Google Scholar
• Nejman D, Livyatan I, Fuks G, Gavert N, Zwang Y, Geller LT, Rotter-Maskowitz A, Weiser R, Mallel G, Gigi E, et al. The human tumor microbiome is composed of tumor type-specific intracellular bacteria. Sci. 2020;368(6494):973–980. doi:10.1126/science.aay9189.
   PubMed Web of Science ®Google Scholar
• Liu Y, Baba Y, Ishimoto T, Tsutsuki H, Zhang T, Nomoto D, Okadome K, Yamamura K, Harada K, Eto K, et al. Fusobacterium nucleatum confers chemoresistance by modulating autophagy in oesophageal squamous cell carcinoma. Br J Cancer. 2021;124(5):963–974. doi:10.1038/s41416-020-01198-5.
   PubMed Web of Science ®Google Scholar
• Wang X, Liu Y, Lu Y, Chen S, Xing Y, Yang H, Wang X, Zhang Y, Pan T, Li J, et al. Clinical impact of Fn-induced high expression of KIR2DL1 in CD8 T lymphocytes in oesophageal squamous cell carcinoma. Ann Med. 2022;54(1):51–62. doi:10.1080/07853890.2021.2016942.
   PubMed Web of Science ®Google Scholar
• Zhang N, Liu Y, Yang H, Liang M, Wang X, Wang M, Kong J, Yuan X, Zhou F. Clinical Significance of Fusobacterium nucleatum Infection and Regulatory T Cell Enrichment in Esophageal Squamous Cell Carcinoma. Pathol Oncol Res. 2021;27:1609846. doi:10.3389/pore.2021.1609846.
   PubMed Web of Science ®Google Scholar
• Kosumi K, Baba Y, Yamamura K, Nomoto D, Okadome K, Yagi T, Toihata T, Kiyozumi Y, Harada K, Eto K, et al. Intratumour Fusobacterium nucleatum and immune response to oesophageal cancer. Br J Cancer. 2023;128(6):1155–1165. doi:10.1038/s41416-022-02112-x.
   PubMed Web of Science ®Google Scholar
• Park H, Clark E, Cullen JJ, Koland JG, Kim MS, Conklin JL. Expression of inducible nitric oxide synthase in the lower esophageal sphincter of the endotoxemic opossum. J Gastroenterol. 2002;37(12):1000–1004. doi:10.1007/s005350200169.
   PubMed Web of Science ®Google Scholar
• Ding N, Cheng Y, Liu H, Wu Y, Weng Y, Cui H, Cheng C, Zhang W, Cui Y, Doucet-Populaire FC. Fusobacterium nucleatum infection induces malignant proliferation of esophageal squamous cell carcinoma cell by putrescine production. Microbiol Spectr. 2023;11(2):e0275922. doi:10.1128/spectrum.02759-22.
   PubMed Web of Science ®Google Scholar
• Boehm ET, Thon C, Kupcinskas J, Steponaitiene R, Skieceviciene J, Canbay A, Malfertheiner P, Link A. Fusobacterium nucleatum is associated with worse prognosis in Lauren’s diffuse type gastric cancer patients. Sci Rep. 2020;10(1):16240. doi:10.1038/s41598-020-73448-8.
   PubMed Web of Science ®Google Scholar
• Hsieh YY, Tung SY, Pan HY, Chang TS, Wei KL, Chen WM, Deng YF, Lu CK, Lai YH, Wu CS, et al. Fusobacterium nucleatum colonization is associated with decreased survival of helicobacter pylori-positive gastric cancer patients. World J Gastroenterol. 2021;27(42):7311–7323. doi:10.3748/wjg.v27.i42.7311.
   PubMed Web of Science ®Google Scholar
• Zhou T, Meng X, Wang D, Fu W, Li X, Acharya A. Neutrophil Transcriptional Deregulation by the Periodontal Pathogen Fusobacterium nucleatum in Gastric Cancer: A Bioinformatic Study, Dis Markers 2022 (2022) 9584507. Dis Markers. 2022. 2022:1–10. doi:10.1155/2022/9584507.
   Web of Science ®Google Scholar
• Baidoun F, Elshiwy K, Elkeraie Y, Merjaneh Z, Khoudari G, Sarmini MT, Gad M, Al-Husseini M, Saad A. Colorectal cancer epidemiology: recent trends and impact on outcomes. Curr Drug Targets. 2021;22(9):998–1009. doi:10.2174/18735592MTEx9NTk2y.
   PubMed Web of Science ®Google Scholar
• Li R, Zhou R, Wang H, Li W, Pan M, Yao X, Zhan W, Yang S, Xu L, Ding Y, et al. Gut microbiota-stimulated cathepsin K secretion mediates TLR4-dependent M2 macrophage polarization and promotes tumor metastasis in colorectal cancer. Cell Death Differ. 2019;26(11):2447–2463. doi:10.1038/s41418-019-0312-y.
   PubMed Web of Science ®Google Scholar
• Kashani N, Bezmin Abadi AT, Rahimi F, Forootan M. FadA-positive Fusobacterium nucleatum is prevalent in biopsy specimens of Iranian patients with colorectal cancer. New Microbes New Infect. 2020;34:100651. doi:10.1016/j.nmni.2020.100651.
   PubMed Web of Science ®Google Scholar
• Xu Z, Zhou Z, Zhang J, Xuan F, Fan M, Zhou D, Liuyang Z, Ma X, Hong Y, Wang Y, et al. Targeting BMI-1-mediated epithelial-mesenchymal transition to inhibit colorectal cancer liver metastasis. Acta Pharm Sin B. 2021;11(5):1274–1285. doi:10.1016/j.apsb.2020.11.018.
   PubMed Web of Science ®Google Scholar
• Sieminska I, Baran J, Myeloid-derived suppressor cells in colorectal cancer, Front Immunol 11 (2020) 1526. 10.3389/fimmu.2020.01526
   Google Scholar
• Al-Mterin MA, Elkord E. Myeloid-derived suppressor cells in colorectal cancer: prognostic biomarkers and therapeutic targets. Explor Target Antitumor Ther. 2022;3(4):497–510. doi:10.37349/etat.2022.00097.
   PubMedGoogle Scholar
• Wu Z, Ma Q, Guo Y, You F. 2022. The Role of Fusobacterium nucleatum in Colorectal Cancer Cell Proliferation and Migration. Cancers Basel. 1421: 10.3390/cancers14215350.
   Web of Science ®Google Scholar
• Zhao P, Zhang Z. TNF-alpha promotes colon cancer cell migration and invasion by upregulating TROP-2. Oncol Lett. 2018;15(3):3820–3827. doi:10.3892/ol.2018.7735.
   PubMed Web of Science ®Google Scholar
• Hayes CL, Dong J, Galipeau HJ, Jury J, McCarville J, Huang X, Wang XY, Naidoo A, Anbazhagan AN, Libertucci J, et al. Commensal microbiota induces colonic barrier structure and functions that contribute to homeostasis. Sci Rep. 2018;8(1):14184. doi:10.1038/s41598-018-32366-6.
   PubMedGoogle Scholar
• Loo TM, Kamachi F, Watanabe Y, Yoshimoto S, Kanda H, Arai Y, Nakajima-Takagi Y, Iwama A, Koga T, Sugimoto Y, et al. Gut microbiota promotes obesity-associated liver cancer through PGE(2)-mediated suppression of antitumor immunity. Cancer Discov. 2017;7(5):522–538. doi:10.1158/2159-8290.Cd-16-0932.
   PubMed Web of Science ®Google Scholar
• Nosho K, Sukawa Y, Adachi Y, Ito M, Mitsuhashi K, Kurihara H, Kanno S, Yamamoto I, Ishigami K, Igarashi H, et al. Association of Fusobacterium nucleatum with immunity and molecular alterations in colorectal cancer. World J Gastroenterol. 2016;22(2):557–566. doi:10.3748/wjg.v22.i2.557.
   PubMed Web of Science ®Google Scholar
• Fathi M, Pustokhina I, Kuznetsov SV, Khayrullin M, Hojjat-Farsangi M, Karpisheh V, Jalili A, Jadidi-Niaragh F. T-cell immunoglobulin and ITIM domain, as a potential immune checkpoint target for immunotherapy of colorectal cancer. Iubmb Life. 2021;73(5):726–738. doi:10.1002/iub.2461.
   PubMed Web of Science ®Google Scholar
• Gur C, Maalouf N, Shhadeh A, Berhani O, Singer BB, Bachrach G, Mandelboim O. Fusobacterium nucleatum supresses anti-tumor immunity by activating CEACAM1. Oncoimmunology. 2019;8(6):e1581531. doi:10.1080/2162402x.2019.1581531.
   PubMed Web of Science ®Google Scholar
• Yang Y, Weng W, Peng J, Hong L, Yang L, Toiyama Y, Gao R, Liu M, Yin M, Pan C, et al. Fusobacterium nucleatum increases proliferation of colorectal cancer cells and tumor development in mice by activating toll-like receptor 4 signaling to nuclear Factor−κB, and up-regulating expression of MicroRNA-21. Gastroenterology. 2017;152(4):851–866.e24. doi:10.1053/j.gastro.2016.11.018.
   PubMed Web of Science ®Google Scholar
• Manfioletti G, Fedele M. Epithelial–mesenchymal transition (EMT) 2021. Int J Mol Sci. 2022;23(10):5848. doi:10.3390/ijms23105848.
   PubMed Web of Science ®Google Scholar
• Xu C, Fan L, Lin Y, Shen W, Qi Y, Zhang Y, Chen Z, Wang L, Long Y, Hou T, et al. Fusobacterium nucleatum promotes colorectal cancer metastasis through miR-1322/CCL20 axis and M2 polarization. Gut Microbes. 2021;13(1):1980347. doi:10.1080/19490976.2021.1980347.
   PubMed Web of Science ®Google Scholar
• Li H, Shen S, Chen X, Ren Z, Li Z, Yu Z. miR-450b-5p loss mediated KIF26B activation promoted hepatocellular carcinoma progression by activating PI3K/AKT pathway. Cancer Cell Int. 2019;19(1):205. doi:10.1186/s12935-019-0923-x.
   PubMedGoogle Scholar
• Gu S, Liang H, Qi D, Mao L, Mao G, Qian L, Zhang S. Knockdown of KIF26B inhibits breast cancer cell proliferation, migration, and invasion. Onco Targets Ther. 2018;11:3195–3203. doi:10.2147/ott.S163346.
   PubMed Web of Science ®Google Scholar
• Basu AK. DNA damage, mutagenesis and cancer. Int J Mol Sci. 2018;19(4):970. doi:10.3390/ijms19040970.
   PubMed Web of Science ®Google Scholar
• Liu Y, Li X, Zhang B, Fu Y, Yang A, Zhang H, Zhang H, Niu Y, Nie J, Yang J. CYP1A1 methylation mediates the effect of smoking and occupational polycyclic aromatic hydrocarbons co-exposure on oxidative DNA damage among Chinese coke-oven workers. Environ Health. 2019;18(1):69. doi:10.1186/s12940-019-0508-0.
   PubMedGoogle Scholar
• Huang R, Zhou PK. DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy. Signal Transduct Target Ther. 2021;6(1):254. doi:10.1038/s41392-021-00648-7.
   PubMed Web of Science ®Google Scholar
• Okita Y, Koi M, Takeda K, Ross R, Mukherjee B, Koeppe E, Stoffel EM, Galanko JA, McCoy AN, Keku TO, et al. Fusobacterium nucleatum infection correlates with two types of microsatellite alterations in colorectal cancer and triggers DNA damage. Gut Pathog. 2020;12(1):46. doi:10.1186/s13099-020-00384-3.
   PubMed Web of Science ®Google Scholar
• Qu R, Zhang Y, Ma Y, Zhou X, Sun L, Jiang C, Zhang Z, Fu W. Role of the gut microbiota and its metabolites in tumorigenesis or development of colorectal cancer. Adv Sci (Weinh). 2023;10(23):e2205563. doi:10.1002/advs.202205563.
   PubMedGoogle Scholar
• Najafi M, Farhood B, Mortezaee K. Cancer stem cells (CSCs) in cancer progression and therapy. J Cell Physiol. 2019;234(6):8381–8395. doi:10.1002/jcp.27740.
   PubMed Web of Science ®Google Scholar
• Ternes D, Tsenkova M, Pozdeev VI, Meyers M, Koncina E, Atatri S, Schmitz M, Karta J, Schmoetten M, Heinken A, et al. The gut microbial metabolite formate exacerbates colorectal cancer progression. Nat Metabolism. 2022;4(4):458–475. doi:10.1038/s42255-022-00558-0.
   PubMedGoogle Scholar
• Guo P, Tian Z, Kong X, Yang L, Shan X, Dong B, Ding X, Jing X, Jiang C, Jiang N, et al. FadA promotes DNA damage and progression of Fusobacterium nucleatum-induced colorectal cancer through up-regulation of chk2. J Exp Clin Cancer Res. 2020;39(1):202. doi:10.1186/s13046-020-01677-w.
   PubMed Web of Science ®Google Scholar
• Rubinstein MR, Baik JE, Lagana SM, Han RP, Raab WJ, Sahoo D, Dalerba P, Wang TC, Han YW. 2019. Fusobacterium nucleatum promotes colorectal cancer by inducing Wnt/β-catenin modulator Annexin A1. EMBO Rep. 204: 10.15252/embr.201847638.
   PubMed Web of Science ®Google Scholar
• Ganesan K, Guo S, Fayyaz S, Zhang G, Xu B. Targeting programmed Fusobacterium nucleatum Fap2 for colorectal cancer therapy. Cancers Basel. 2019;11(10):1592. doi:10.3390/cancers11101592.
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492.
   PubMed Web of Science ®Google Scholar
• Yang G, Yang Y, Tang H, Yang K. Loss of the clock gene Per1 promotes oral squamous cell carcinoma progression via the AKT/mTOR pathway. Cancer Sci. 2020;111(5):1542–1554. doi:10.1111/cas.14362.
   PubMed Web of Science ®Google Scholar
• Blahak J, Zelinka J, Gumulec J, Machacek C, Danek Z, Bulik O. HPV, protein p16 and squamous cell carcinoma of the oral cavity. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2020;164(3):292–299. doi:10.5507/bp.2019.026.
   PubMed Web of Science ®Google Scholar
• Capote-Moreno A, Brabyn P, Muñoz-Guerra MF, Sastre-Pérez J, Escorial-Hernandez V, Rodríguez-Campo FJ, García T, Naval-Gías L. Oral squamous cell carcinoma: epidemiological study and risk factor assessment based on a 39-year series. Int J Oral Maxillofac Surg. 2020;49(12):1525–1534. doi:10.1016/j.ijom.2020.03.009.
   PubMed Web of Science ®Google Scholar
• Mark Welch JL, Ramírez-Puebla ST, Borisy GG. Oral Microbiome Geography: Micron-Scale Habitat and Niche. Cell Host & Microbe. 2020;28(2):160–168. doi:10.1016/j.chom.2020.07.009.
   PubMed Web of Science ®Google Scholar
• Mondal S, Adhikari N, Banerjee S, Amin SA, Jha T. Matrix metalloproteinase-9 (MMP-9) and its inhibitors in cancer: a minireview. Eur J Med Chem. 2020;194:112260. doi:10.1016/j.ejmech.2020.112260.
   PubMed Web of Science ®Google Scholar
• Harrandah AM, Chukkapalli SS, Bhattacharyya I, Progulske-Fox A, Chan EKL. Fusobacteria modulate oral carcinogenesis and promote cancer progression. J Oral Microbiol. 2020;13(1):1849493. doi:10.1080/20002297.2020.1849493.
   PubMed Web of Science ®Google Scholar
• Kelley N, Jeltema D, Duan Y, He Y. The NLRP3 inflammasome: an overview of mechanisms of activation and regulation. Int J Mol Sci. 2019;20(13):3328. doi:10.3390/ijms20133328.
   PubMed Web of Science ®Google Scholar
• Chen G, Sun Q, Cai Q, Zhou H. Outer membrane vesicles from fusobacterium nucleatum switch M0-like macrophages toward the M1 phenotype to destroy periodontal tissues in mice. Front Microbiol. 2022;13:815638. doi:10.3389/fmicb.2022.815638.
   PubMed Web of Science ®Google Scholar
• Dongre A, Weinberg RA. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 2019;20(2):69–84. doi:10.1038/s41580-018-0080-4.
   PubMed Web of Science ®Google Scholar
• Puram SV, Tirosh I, Parikh AS, Patel AP, Yizhak K, Gillespie S, Rodman C, Luo CL, Mroz EA, Emerick KS, et al. Single-cell transcriptomic analysis of primary and metastatic tumor ecosystems in head and neck cancer. Cell. 2017;171(7):1611–1624.e24. doi:10.1016/j.cell.2017.10.044.
   PubMed Web of Science ®Google Scholar
• Ling Z, Cheng B, Tao X. Epithelial-to-mesenchymal transition in oral squamous cell carcinoma: challenges and opportunities. Int J Cancer. 2021;148(7):1548–1561. doi:10.1002/ijc.33352.
   PubMed Web of Science ®Google Scholar
• Shao W, Fujiwara N, Mouri Y, Kisoda S, Yoshida K, Yoshida K, Yumoto H, Ozaki K, Ishimaru N, Kudo Y. Conversion from epithelial to partial-EMT phenotype by Fusobacterium nucleatum infection promotes invasion of oral cancer cells. Sci Rep. 2021;11(1):14943. doi:10.1038/s41598-021-94384-1.
   PubMed Web of Science ®Google Scholar
• Stasiewicz M, Karpiński TM. The oral microbiota and its role in carcinogenesis. Semin Cancer Biol. 2022;86(Pt 3):633–642. doi:10.1016/j.semcancer.2021.11.002.
   PubMedGoogle Scholar
• Weng S, Ruan H. Multi-omics characterization of synthetic lethality-related molecular features: implications for SL-based therapeutic target screening. FEBS J. 2022;290(6):1477–1480. doi:10.1111/febs.16692.
   PubMed Web of Science ®Google Scholar
• Huang J, Lok V, Ngai CH, Zhang L, Yuan J, Lao XQ, Ng K, Chong C, Zheng Z-J, Wong MCS. Worldwide burden of risk factors for, and trends in pancreatic cancer. Gastroenterology. 2021;160(3):744–754. doi:10.1053/j.gastro.2020.10.007.
   PubMed Web of Science ®Google Scholar
• Cai J, Chen H, Lu M, Zhang Y, Lu B, You L, Zhang T, Dai M, Zhao Y. Advances in the epidemiology of pancreatic cancer: trends, risk factors, screening, and prognosis. Cancer Lett. 2021;520:1–11. doi:10.1016/j.canlet.2021.06.027.
   PubMed Web of Science ®Google Scholar
• Klein AP. Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors. Nat Rev Gastroenterol Hepatol. 2021;18(7):493–502. doi:10.1038/s41575-021-00457-x.
   PubMed Web of Science ®Google Scholar
• Riquelme E, Zhang Y, Zhang L, Montiel M, Zoltan M, Dong W, Quesada P, Sahin I, Chandra V, San Lucas A, et al. Tumor microbiome diversity and composition influence pancreatic cancer outcomes. Cell. 2019;178(4):795–806.e12. doi:10.1016/j.cell.2019.07.008.
   PubMed Web of Science ®Google Scholar
• Pushalkar S, Hundeyin M, Daley D, Zambirinis CP, Kurz E, Mishra A, Mohan N, Aykut B, Usyk M, Torres LE, et al. The pancreatic cancer microbiome promotes oncogenesis by induction of innate and adaptive immune suppression. Cancer Discov. 2018;8(4):403–416. doi:10.1158/2159-8290.Cd-17-1134.
   PubMed Web of Science ®Google Scholar
• Udayasuryan B, Ahmad RN, Nguyen TTD, Umaña A, Monét Roberts L, Sobol P, Jones SD, Munson JM, Slade DJ, Verbridge SS. Fusobacterium nucleatum induces proliferation and migration in pancreatic cancer cells through host autocrine and paracrine signaling. Sci Signal. 2022;15(756):eabn4948. doi:10.1126/scisignal.abn4948.
   PubMed Web of Science ®Google Scholar
• Hayashi M, Ikenaga N, Nakata K, Luo H, Zhong P, Date S, Oyama K, Higashijima N, Kubo A, Iwamoto C, et al. Intratumor Fusobacterium nucleatum promotes the progression of pancreatic cancer via the CXCL1-CXCR2 axis. Cancer Sci. 2023;114(9):3666–3678. doi:10.1111/cas.15901.
   PubMed Web of Science ®Google Scholar
• Morgan E, Soerjomataram I, Rumgay H, Coleman HG, Thrift AP, Vignat J, Laversanne M, Ferlay J, Arnold M. The Global Landscape of Esophageal Squamous Cell Carcinoma and Esophageal Adenocarcinoma Incidence and Mortality in 2020 and Projections to 2040: New Estimates From GLOBOCAN 2020. Gastroenterology. 2022;163(3):649–658 e2. doi:10.1053/j.gastro.2022.05.054.
   PubMed Web of Science ®Google Scholar
• Plaza-Diaz J, Alvarez-Mercado AI, Ruiz-Marin CM, Reina-Perez I, Perez-Alonso AJ, Sanchez-Andujar MB, Torne P, Gallart-Aragon T, Sanchez-Barron MT, Reyes Lartategui S, et al. Association of breast and gut microbiota dysbiosis and the risk of breast cancer: a case-control clinical study. BMC Cancer. 2019;19(1):495. doi:10.1186/s12885-019-5660-y.
   PubMedGoogle Scholar
• Gaba FI, Gonzalez RC, Martinez RG, Isola G. The role of oral Fusobacterium nucleatum in female breast cancer: a systematic review and meta-analysis. Int J Dent. 2022. 2022:1–12. doi:10.1155/2022/1876275.
   Web of Science ®Google Scholar
• Wei MQ, Ellem KA, Dunn P, West MJ, Bai CX, Vogelstein B. Facultative or obligate anaerobic bacteria have the potential for multimodality therapy of solid tumours. Eur J Cancer. 2007;43(3):490–496. doi:10.1016/j.ejca.2006.10.005.
   PubMed Web of Science ®Google Scholar
• Gillespie MR, Rai V, Agrawal S, Nandipati KC. 2021. The role of microbiota in the pathogenesis of esophageal adenocarcinoma. Biology (Basel). 108: 10.3390/biology10080697.
   PubMedGoogle Scholar
• Muszynski D, Kudra A, Sobocki BK, Folwarski M, Vitale E, Filetti V, Dudzic W, Kazmierczak-Siedlecka K, Polom K. Esophageal cancer and bacterial part of gut microbiota - a multidisciplinary point of view. Front Cell Infect Microbiol. 2022;12:1057668. doi:10.3389/fcimb.2022.1057668.
   PubMed Web of Science ®Google Scholar
• Li Z, Shi C, Zheng J, Guo Y, Fan T, Zhao H, Jian D, Cheng X, Tang H, Ma J. Fusobacterium nucleatum predicts a high risk of metastasis for esophageal squamous cell carcinoma. BMC Microbiol. 2021;21(1):301. doi:10.1186/s12866-021-02352-6.
   PubMed Web of Science ®Google Scholar
• Machlowska J, Baj J, Sitarz M, Maciejewski R, Sitarz R. Gastric cancer: epidemiology, risk factors, classification, genomic characteristics and treatment strategies. Int J Mol Sci. 2020;21(11):4012. doi:10.3390/ijms21114012.
   PubMed Web of Science ®Google Scholar
• Stewart OA, Wu F, Chen Y. The role of gastric microbiota in gastric cancer. Gut Microbes. 2020;11(5):1220–1230. doi:10.1080/19490976.2020.1762520.
   PubMed Web of Science ®Google Scholar
• Wang L, Zhou J, Xin Y, Geng C, Tian Z, Yu X, Dong Q. Bacterial overgrowth and diversification of microbiota in gastric cancer. Eur J Gastroenterol Hepatol. 2016;28(3):261–266. doi:10.1097/MEG.0000000000000542.
   PubMed Web of Science ®Google Scholar
• Liatsos C, Papaefthymiou A, Kyriakos N, Galanopoulos M, Doulberis M, Giakoumis M, Petridou E, Mavrogiannis C, Rokkas T, Kountouras J. Helicobacter pylori, gastric microbiota and gastric cancer relationship: unrolling the tangle. World J Gastrointest Oncol. 2022;14(5):959–972. doi:10.4251/wjgo.v14.i5.959.
   PubMed Web of Science ®Google Scholar
• Rubinstein MR, Wang X, Liu W, Hao Y, Cai G, Han YW. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/beta-catenin signaling via its FadA adhesin. Cell Host & Microbe. 2013;14(2):195–206. doi:10.1016/j.chom.2013.07.012.
   PubMed Web of Science ®Google Scholar
• Xin Y, Li X, Zhang M, Shang Z, Luo Z, Wang Y, Gui X, Liu Q, Li T, Zeng S, et al. Fusobacterium nucleatum-induced exosomal HOTTIP promotes gastric cancer progression through the microRNA-885-3p/EphB2 axis. Cancer Sci. 2023;114(6):2360–2374. doi:10.1111/cas.15781.
   PubMed Web of Science ®Google Scholar
• Jiang S-S, Xie Y-L, Xiao X-Y, Kang Z-R, Lin X-L, Zhang L, Li C-S, Qian Y, Xu P-P, Leng X-X, et al. Fusobacterium nucleatum-derived succinic acid induces tumor resistance to immunotherapy in colorectal cancer. Cell Host & Microbe. 2023;31(5):781–797.e9. doi:10.1016/j.chom.2023.04.010.
   PubMed Web of Science ®Google Scholar
• LaCourse KD, Zepeda-Rivera M, Kempchinsky AG, Baryiames A, Minot SS, Johnston CD, Bullman S. The cancer chemotherapeutic 5-fluorouracil is a potent Fusobacterium nucleatum inhibitor and its activity is modified by intratumoral microbiota. Cell Rep. 2022;41(7):111625. doi:10.1016/j.celrep.2022.111625.
   PubMed Web of Science ®Google Scholar
• Yu T, Guo F, Yu Y, Sun T, Ma D, Han J, Qian Y, Kryczek I, Sun D, Nagarsheth N, et al. Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy. Cell. 2017;170(3):548–563.e16. doi:10.1016/j.cell.2017.07.008.
   PubMed Web of Science ®Google Scholar
• Alon-Maimon T, Mandelboim O, Bachrach G. Fusobacterium nucleatum and cancer. Periodontology. 2022;89(1):166–180. doi:10.1111/prd.12426.
   Google Scholar
• Liang M, Liu Y, Zhang Z, Yang H, Dai N, Zhang N, Sun W, Guo Y, Kong J, Wang X, et al. Fusobacterium nucleatum induces MDSCs enrichment via activation the NLRP3 inflammosome in ESCC cells, leading to cisplatin resistance. Ann Med. 2022;54(1):989–1003. doi:10.1080/07853890.2022.2061045.
   PubMed Web of Science ®Google Scholar
• Zhang J-W, Zhang D, Yin H-S, Zhang H, Hong K-Q, Yuan J-P, Yu B-P. Fusobacterium nucleatum promotes esophageal squamous cell carcinoma progression and chemoresistance by enhancing the secretion of chemotherapy-induced senescence-associated secretory phenotype via activation of DNA damage response pathway. Gut Microbes. 2023;15(1):2197836. doi:10.1080/19490976.2023.2197836.
   PubMed Web of Science ®Google Scholar
• Da J, Wang X, Li L, Xu Y. Fusobacterium nucleatum promotes cisplatin-resistance and migration of oral squamous carcinoma cells by up-regulating Wnt5a-mediated NFATc3 expression. Tohoku J Exp Med. 2021;253(4):249–259. doi:10.1620/tjem.253.249.
   PubMed Web of Science ®Google Scholar
• Liu K, Yang X, Zeng M, Yuan Y, Sun J, He P, Sun J, Xie Q, Chang X, Zhang S, et al. The role of fecal Fusobacterium nucleatum and pks+ Escherichia coli as early diagnostic markers of colorectal cancer, disease markers 2021. Dis Markers. 2021. 2021:1–11. doi:10.1155/2021/1171239.
   Web of Science ®Google Scholar
• Kurt M, Yumuk Z, Diagnostic accuracy of Fusobacterium nucleatum IgA and IgG ELISA test in colorectal cancer, Sci Rep 11 (1) (2021) 1608. 10.1038/s41598-021-81171-1
   Google Scholar
• Baik JE, Li L, Shah MA, Freedberg DE, Jin Z, Wang TC, Han YW. Circulating IgA antibodies against Fusobacterium nucleatum amyloid adhesin FadA are a potential biomarker for colorectal neoplasia. Cancer Res Commun. 2022;2(11):1497–1503. doi:10.1158/2767-9764.Crc-22-0248.
   PubMedGoogle Scholar
• Chattopadhyay I, Verma M, Panda M. Role of Oral Microbiome Signatures in Diagnosis and Prognosis of Oral Cancer. Technol Cancer Res Treat. 2019;18:1533033819867354. doi:10.1177/1533033819867354.
   Web of Science ®Google Scholar
• Chen Z, Wong PY, Ng CWK, Lan L, Fung S, Li JW, Cai L, Lei P, Mou Q, Wong SH, et al. The intersection between oral microbiota, host gene methylation and patient outcomes in head and neck squamous cell carcinoma. Cancers. 2020;12(11):3425. doi:10.3390/cancers12113425.
   PubMed Web of Science ®Google Scholar
• Chen WD, Zhang X, Zhang MJ, Zhang YP, Shang ZQ, Xin YW, Zhang Y. Salivary Fusobacterium nucleatum serves as a potential diagnostic biomarker for gastric cancer. World J Gastroenterol. 2022;28(30):4120–4132. doi:10.3748/wjg.v28.i30.4120.
   PubMed Web of Science ®Google Scholar
• Ting NL-N, Lau HC-H, Yu J. Cancer pharmacomicrobiomics: targeting microbiota to optimise cancer therapy outcomes. Gut. 2022;71(7):1412–1425. doi:10.1136/gutjnl-2021-326264.
   PubMed Web of Science ®Google Scholar
• Jia F, Yu Q, Wang R, Zhao L, Yuan F, Guo H, Shen Y, He F. Optimized Antimicrobial Peptide Jelleine-I Derivative Br-J-I Inhibits Fusobacterium Nucleatum to Suppress Colorectal Cancer Progression. Int J Mol Sci. 2023;24(2):1469. doi:10.3390/ijms24021469.
   PubMed Web of Science ®Google Scholar
• Van der Merwe M, Van Niekerk G, Botha A, Engelbrecht A-M. The onco-immunological implications of Fusobacterium nucleatum in breast cancer. Immunol Lett. 2021. 232:60–66. doi:10.1016/j.imlet.2021.02.007.
   PubMed Web of Science ®Google Scholar
• Yamaoka Y, Suehiro Y, Hashimoto S, Hoshida T, Fujimoto M, Watanabe M, Imanaga D, Sakai K, Matsumoto T, Nishioka M, et al. Fusobacterium nucleatum as a prognostic marker of colorectal cancer in a Japanese population. J Gastroenterol. 2018;53(4):517–524. doi:10.1007/s00535-017-1382-6.
   PubMed Web of Science ®Google Scholar
• Kunzmann AT, Proença MA, Jordao HW, Jiraskova K, Schneiderova M, Levy M, Liska V, Buchler T, Vodickova L, Vymetalkova V, et al. Fusobacterium nucleatum tumor DNA levels are associated with survival in colorectal cancer patients. Eur J Clin Microbiol Infect Dis. 2019;38(10):1891–1899. doi:10.1007/s10096-019-03649-1.
   PubMed Web of Science ®Google Scholar
• Mima K, Nishihara R, Qian ZR, Cao Y, Sukawa Y, Nowak JA, Yang J, Dou R, Masugi Y, Song M, et al., Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis, Gut 65 (12) (2016) 1973–1980. 10.1136/gutjnl-2015-310101
   Google Scholar
• Lee JB, Kim KA, Cho HY, Kim D, Kim WK, Yong D, Lee H, Yoon SS, Han DH, Han YD, et al. Association between Fusobacterium nucleatum and patient prognosis in metastatic colon cancer. Sci Rep. 2021;11(1):20263. doi:10.1038/s41598-021-98941-6.
   PubMed Web of Science ®Google Scholar
• Mitsuhashi K, Nosho K, Sukawa Y, Matsunaga Y, Ito M, Kurihara H, Kanno S, Igarashi H, Naito T, Adachi Y, et al. Association of Fusobacterium species in pancreatic cancer tissues with molecular features and prognosis. Oncotarget. 2015;6(9):7209–7220. doi:10.18632/oncotarget.3109.
   PubMedGoogle Scholar
• Zhang N, Kandalai S, Zhou X, Hossain F, Zheng Q. Applying multi-omics toward tumor microbiome research. iMeta. 2023;2(1):e73. doi:10.1002/imt2.73.
   Google Scholar